CatalystFDA/Bio

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced

FDA Priority Review and first-in-class

What changed

FDA Priority Review and first-in-class

Why it matters

FDA Priority Review and first-in-class — impact context not separately stored; see What changed.

Sources

Johnson &amp; Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced